TriSalus Life Sciences Inc TLSI
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if TLSI is a good fit for your portfolio.
News
-
TriSalus Reports Q4 and Full Year 2023 Financial Results and Business Update
-
TriSalus Life Sciences Technology Featured in Two Presentations at the Society of Interventional Radiology Annual Scientific Meeting
-
TriSalus Life Sciences Announces Oral Presentations at the Upcoming 2024 Society of Interventional Radiology (SIR) Annual Scientific Meeting
-
TriSalus Life Sciences Announces Q4 Conference Call and Preliminary and Unaudited Q4 and Full Year 2023 Financial Results
-
TriSalus Life Sciences Receives Approval from the World Health Organization and the American Medical Association’s Adopted Name Council for “Nelitolimod” as the Nonproprietary Drug Name for SD-101
-
TriSalus Life Sciences Announces Real-World Data Demonstrating the Ability of TriNav® to Successfully Treat Patients with Higher Disease Burden and to Improve Delivery of Therapeutics to Liver Tumors
Trading Information
- Previous Close Price
- $9.31
- Day Range
- $9.49–9.49
- 52-Week Range
- $3.34–16.24
- Bid/Ask
- $9.28 / $9.77
- Market Cap
- $285.63 Mil
- Volume/Avg
- 10,137 / 42,165
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 4.75
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
TriSalus Life Sciences Inc is engaged in the research, development, and sales of innovative drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product lines Pressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- —
- Total Number of Employees
- —
- Website
- https://www.trisaluslifesci.com
Valuation
|
Metric
|
TLSI
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 4.75 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
TLSI
|
|---|---|
Quick Ratio | 1.04 |
Current Ratio | 1.42 |
Interest Coverage | −3,715.25 |
Quick Ratio
TLSI
Profitability
|
Metric
|
TLSI
|
|---|---|
Return on Assets (Normalized) | −213.07% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
TLSI
Medical Devices Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
ABT
| Abbott Laboratories | Pgstkqxtx | Hzgqnzq | $186.1 Bil | |
SYK
| Stryker Corp | Ljqpdfcbd | Dwjr | $128.9 Bil | |
MDT
| Medtronic PLC | Dzrttzpg | Vjrftw | $107.4 Bil | |
BSX
| Boston Scientific Corp | Nrkhcjxzt | Vgccqd | $106.6 Bil | |
EW
| Edwards Lifesciences Corp | Bzpsnthwgz | Lvxtc | $51.8 Bil | |
DXCM
| DexCom Inc | Dykmymcpx | Pmslg | $49.8 Bil | |
ZBH
| Zimmer Biomet Holdings Inc | Nsggfyfdmy | Vscxb | $25.0 Bil | |
PHG
| Koninklijke Philips NV ADR | Jmhycmjj | Qzvkd | $24.8 Bil | |
ALGN
| Align Technology Inc | Htqlfmfm | Xfwzbr | $22.9 Bil | |
PODD
| Insulet Corp | Tzrslvzgb | Nzpnv | $11.9 Bil |